Information  X 
Enter a valid email address

TARGOVAX ORD (0RIS)

Date Time Source Announcement
03 May 2018 6:02 am
GNW
Targovax ASA: First quarter 2018 results
02 May 2018 6:00 am
GNW
Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
25 Apr 2018 6:00 am
GNW
Targovax presentation at ChinaBio Partnering Forum 2018
24 Apr 2018 6:00 am
GNW
Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May
12 Apr 2018 1:47 pm
GNW
Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
11 Apr 2018 9:40 am
GNW
Targovax ASA: Protocol from the Annual General Meeting
24 Mar 2018 8:16 am
GNW
Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018
15 Mar 2018 6:00 am
GNW
Targovax ASA: Notice of Annual General Meeting
  6:00 am
GNW
Targovax ASA: Annual Report 2017
27 Feb 2018 6:00 am
GNW
Targovax to present at Biologics World Nordic 2018
15 Feb 2018 6:00 am
GNW
Targovax ASA: Fourth quarter and full year 2017 results
07 Feb 2018 6:00 am
GNW
Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
06 Feb 2018 6:00 am
GNW
Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
08 Jan 2018 6:00 am
GNW
Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
04 Jan 2018 6:00 am
GNW
Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
18 Dec 2017 6:00 am
GNW
Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
13 Dec 2017 6:00 am
GNW
Targovax to present at DNB healthcare conference
11 Dec 2017 6:00 am
GNW
Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
30 Nov 2017 1:03 pm
GNW
Targovax ASA: New member of the board of directors
14 Nov 2017 6:00 am
GNW
Targovax to present at upcoming investor conferences
07 Nov 2017 10:39 am
GNW
Targovax ASA: Notice of Extraordinary General Meeting
02 Nov 2017 6:00 am
GNW
Targovax ASA: Third quarter 2017 results
24 Oct 2017 6:00 am
GNW
Targovax ASA: Invitation to third quarter 2017 results presentation Thursday 2 November
12 Oct 2017 6:00 am
GNW
Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer
03 Oct 2017 1:49 pm
GNW
Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
25 Sep 2017 6:00 am
GNW
Targovax granted US Patent for mutant-RAS neoantigen platform lead products
14 Sep 2017 3:00 pm
GNW
Targovax Receives 2017 Nordic Stars Award
11 Sep 2017 6:00 am
GNW
Targovax ASA: Three posters presented at ESMO conference
24 Aug 2017 6:00 am
GNW
Targovax ASA: Second quarter and first half 2017 results
23 Aug 2017 5:31 pm
GNW
Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress
14 Aug 2017 6:00 am
GNW
Targovax ASA: Invitation to second quarter and first half 2017 results presentation Thursday 24 August
09 Jun 2017 2:41 pm
GNW
Targovax ASA: Notice of Extraordinary General Meeting
  6:52 am
GNW
Targovax ASA - Information on the subsequent offering - Key date information
08 Jun 2017 9:30 pm
GNW
TARGOVAX ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
06 Jun 2017 6:01 am
GNW
Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
  6:00 am
GNW
Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
18 May 2017 6:02 am
GNW
Targovax ASA: ASCO abstract released
10 May 2017 7:06 am
GNW
Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
08 May 2017 6:01 am
GNW
Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
25 Apr 2017 6:00 am
GNW
Targovax ASA: First quarter 2017 results
20 Apr 2017 6:01 am
GNW
Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
19 Apr 2017 6:01 am
GNW
Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
06 Apr 2017 6:00 am
GNW
Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
05 Apr 2017 10:11 am
GNW
Targovax ASA: Protocol from the Annual General Meeting
04 Apr 2017 8:05 am
GNW
Targovax ASA: Proposal from the nomination committee to the annual general meeting 5 April 2017
23 Mar 2017 6:01 am
GNW
Targovax ASA moves share listing to Oslo Børs
15 Mar 2017 9:02 pm
GNW
Targovax ASA: Notice of Annual General Meeting
  8:16 pm
GNW
Targovax ASA: Annual Report 2016
06 Mar 2017 6:00 am
GNW
Targovax to present at upcoming conferences
16 Feb 2017 6:01 am
GNW
Targovax ASA: Fourth quarter and full year 2016 results
06 Feb 2017 6:00 am
GNW
Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
02 Feb 2017 9:44 am
GNW
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
05 Jan 2017 6:00 am
GNW
Targovax announces appointment of Erik Digman Wiklund as CFO
13 Dec 2016 6:00 am
GNW
Targovax to present at DNB healthcare conference
17 Nov 2016 6:00 am
GNW
Targovax ASA: Third quarter 2016 results
16 Nov 2016 6:01 am
GNW
Targovax to present at forthcoming conference
10 Nov 2016 6:00 am
GNW
Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
08 Nov 2016 6:00 am
GNW
Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
02 Nov 2016 6:01 am
GNW
Targovax announces appointment of Oystein Soug as CEO
21 Oct 2016 9:00 am
GNW
Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t